Bumetanide

Bumetanide
Clinical data
Trade names	Bumex, Burinex, others
AHFS/Drugs.com	Monograph
MedlinePlus	a684051
License data	US DailyMed: Bumetanide;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth, intravenous, intramuscular
ATC code	C03CA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Almost complete (~80%)
Protein binding	97%
Metabolism	Liver
Elimination half-life	~0.8 hours
Excretion	Kidney
Identifiers
	IUPAC name 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid;
CAS Number	28395-03-1 ;
PubChem CID	2471;
IUPHAR/BPS	4837;
DrugBank	DB00887 ;
ChemSpider	2377 ;
UNII	0Y2S3XUQ5H;
KEGG	D00247 ;
ChEBI	CHEBI:3213 ;
ChEMBL	ChEMBL1072 ;
CompTox Dashboard (EPA)	DTXSID5022699 ;
ECHA InfoCard	100.044.534
Chemical and physical data
Formula	C17H20N2O5S
Molar mass	364.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccccc1Oc2c(NCCCC)cc(C(=O)O)cc2S(=O)(=O)N;
	InChI InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23) ; Key:MAEIEVLCKWDQJH-UHFFFAOYSA-N ;
	(verify)

Bumetanide, sold under the brand name Bumex among others, is a medication used to treat swelling and high blood pressure. This includes swelling as a result of heart failure, liver failure, or kidney problems. It may work for swelling when other medications have not. For high blood pressure it is not a preferred treatment. It is taken by mouth, or by injection into a vein or muscle. Effects generally begin within an hour and last for about six hours.

Common side effects include dizziness, low blood pressure, low blood potassium, muscle cramps, and kidney problems. Other serious side effects may include hearing loss and low blood platelets. Blood tests are recommended regularly for those on treatment. Safety during pregnancy and breastfeeding is unclear. Bumetanide is a loop diuretic and works by decreasing the reabsorption of sodium by the kidneys.

Bumetanide was patented in 1968 and came into medical use in 1972. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2020, it was the 270th most commonly prescribed medication in the United States, with more than 1 million prescriptions.